YW1128 is a potent Wnt/β-catenin inhibitor that induces proteasomal degradation of β-catenin, thereby suppressing Wnt/β-catenin signaling in cells; it significantly reduces hepatic lipid accumulation, improves glucose tolerance in mice fed a high-fat diet without apparent toxicity, and downregulates genes involved in glucose metabolism (PEPCK, G6Pase) and fatty acid synthesis (FASN, ACAA1A, ACOT4, SCD1).